Re: Reports of Exempt Distribution

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Reports of Exempt Distribution

in response to

Reports of Exempt Distribution

KOO-KOO2

posted on Feb 21, 2023 12:58PM

Additional Reports of Exempt Distribution:

2023-01-31: 40,833 Common Shares @ 80 cents CAN = $32,707.00 out of USA

2023-02-10: 2, Convertable Notes CAN $133,362.00 each = $267,240.00 out of USA & Germany with 150,000 share purchase warrants @ 80 cents CAN expire 2028-02-10